Mannan-binding lectin in malignancy.
Complement may play a dual role in cancer: it may contribute either to the development or to the inhibition of tumour growth. Its components may be candidate biomarkers facilitating the disease detection, its progress or effectiveness of therapy. Additionally, complement deficiencies may increase the risk of infections and contribute to the higher mortality, especially in patients undergoing aggressive chemotherapy. In this paper, possible cancer associations of one of the factors activating complement via the lectin pathway, mannan-binding lectin (MBL), are discussed.
Laboratory of Immunobiology of Infections, Institute of Medical Biology, Polish Academy of Sciences, Lodz, Poland.
Anna S
AS
Swierzko
David C
DC
Kilpatrick
Maciej
M
Cedzynski
D000818:Animals; D037582:Complement Pathway, Mannose-Binding Lectin / Q000235:genetics / Q000502:physiology; D006801:Humans; D037601:Mannose-Binding Lectin / Q000235:genetics / Q000378:metabolism / Q000502:physiology*; D008495:Medical Oncology / Q000379:methods / Q000639:trends; D008954:Models, Biological; D009369:Neoplasms / Q000209:etiology* / Q000235:genetics / Q000378:metabolism; D055503:Protein Multimerization / Q000235:genetics / Q000502:physiology
D037601:Mannose-Binding Lectin